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Aim: The administration of b2-agonists to patients with airways obstruction often results in
transient decrease in PaO2 despite concomitant bronchodilation. This effect is potentially
dangerous for patients suffering from acute exacerbation of COPD (AECOPD). In this study,
we investigated the effect of indacaterol 150 mg and 300 mg on the arterial blood gas tensions
of hospitalised patients with AECOPD.
Methods: We explored the acute effects on arterial blood gases and spirometry of two doses of
indacaterol Breezhaler (150 and 300 mg) in 12 patients hospitalised because of an AECOPD in 2
non-consecutive days under open-label, randomized, crossover conditions, with blind evalua-
tion. Blood specimens were taken just before the inhalation and at 15, 30, 60, 120, 240 and
360 min after inhalation of each treatment, and spirometry was performed at the same time
points.
Results: Both doses of indacaterol did not cause significant changes in blood gases, although
some patients with relatively well-preserved PaO2 presented transient episodes of oxygen de-
saturation that normalize spontaneously in a very short time. Moreover, they induced a signif-
icant mean increase in FEV1 and FVC, although the improvement caused by indacaterol 300 mg
was larger.
Conclusions: Indacaterol up to 300 mg is a potent bronchodilator that may induce small, tran-
sient decrease in PaO2 mainly in patients with relatively well-preserved PaO2. There appeared
to be no clinical consequences of these PaO2 abnormalities in patients suffering from AECOPD.
ª 2013 Published by Elsevier Ltd.of System Medicine, University of Rome ‘Tor Vergata’, Via Montpellier 1, 00133 Rome, Italy.
iroma2.it (M. Cazzola).
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when physician observed a sustained worsening of the pa-Short-acting inhaled b2-agonists (SABAs) such as salbutamol
and terbutaline are usually the preferred bronchodilators for
treatment of acute exacerbations of chronic obstructive
pulmonary disease (AECOPD) [1]. Actually, some studies
suggest that these agents, as a class, are of benefit in
AECOPD, showing improvements in lung function and dysp-
noea scores [2]. However, there is a great deal of controversy
regarding the timing and optimal dose of SABAs, also
considering that the duration of the bronchodilator effect of
SABAs is decreased in AECOPD [3]. For this reason, several
authors suggest not only using larger-than-usual doses that
are sometimes necessary to relieve airway obstruction, but
also to shorten the posologic interval [2,4].
The use of long-acting, inhaled b2-agonists (LABAs) for-
moterol and salmeterol should beanother potential option to
overcome the reduced functional half-life of SABAs in
AECOPD, although they are still not approved for use in this
pathologic condition [5]. This assumption is supported by
results of small studies suggesting a potential use of LABAs
during AECOPD [6e9]. This is particularly true for formoterol
because of its rapid onset and long duration of action.
Indacaterol is the first once-daily LABA approved as a
maintenance bronchodilator treatment of airflow obstruc-
tion in adult patients with COPD [10,11]. Single doses of
indacaterol 150 and 300 mg demonstrate a fast onset of
action similar to that for salbutamol [12]. The rapid onset
of action, duration of bronchodilation for at least 24 h, and
an optimal safety profile make this drug an interesting
therapeutic option in AECOPD, although indacaterol has be
approved only for the treatment of stable COPD. However,
no study has yet assessed the impact of this once-daily
LABA on partial pressure of oxygen in arterial blood (PaO2).
This is a potential limitation to the use of indacaterol in
AECOPD because the administration of b2-agonists to pa-
tients with airways obstruction often results in a transient
decrease in PaO2 despite concomitant bronchodilation [13],
although hypoxaemia induced by b2-agonists is usually mild,
at least in stable COPD [14,15]. Nonetheless, this effect
could be potentially dangerous for patients suffering from
AECOPD. In fact, AECOPD are frequently associated with
deterioration in gas exchange and hypoxaemia. Increased
inequality in ventilationeperfusion (VA/Q) relationships
appears to be the major determinant of these changes [16].
In stable COPDwe already observed that the inhalation of
indacaterol 150 mg induced amodest but significant decrease
in blood oxygen saturation (SpO2) up to 60 min and a second
dose of indacaterol 150 mg significantly decreased the SpO2
mean value up to 360 min [17]. Since the decrease in SpO2
could be potentially dangerous for patients suffering from
AECOPD and hypoxaemia, we aimed to investigate the acute
effects of indacaterol inhalation on the arterial blood gas
tensions of hospitalized patients with AECOPD.
Patients and methods
Study population
Twelve Caucasian patients admitted to our Unit were
recruited on the basis of having an AECOPD requiringhospitalization. The presence of an AECOPD was diagnosed
tient’s condition, from the stable state and beyond normal
day-to-day variations, necessitating a change in regular
medication in a patient with underlying COPD [18]. Exacer-
bations were considered severe because patient/physician
recognised obvious and/or rapid deterioration in condition,
requiring hospitalisation [18]. Because of the severity of the
exacerbation, all patients, who had been transferred to our
Unit fromtheEmergencyRoomwhen theywere improvedbut
still needed a period of monitoring before discharge, had an
arterial catheter placed in the brachial artery during their
stay in the Emergency Room to facilitate monitoring of
arterial blood gases. Arterial catheterization is used nor-
mally in the management of critically ill patients, both for
continuous blood pressure monitoring and access to the
arterial circulation to obtain frequent blood gas measure-
ments [19]. The exclusion criteria were: personal or family
history of asthma, atopy, allergic disease, presence of
eosinophilia, use of systemic steroids within the preceding
month, presence of severe hypertension, or uncontrolled (or
difficult to control) diabetes mellitus, or if a specific cause
for the exacerbation, such as pneumonia, pneumothorax, or
heart failure, was diagnosed. Patients were also excluded if
they were at risk of imminent acute respiratory failure
requiring mechanical ventilation or admission to the inten-
sive care unit (pH < 7.30 and/or PaCO2 > 70 mmHg, and/or
PaO2< 50 mmHg despite supplemental oxygen). None of the
patients was b2-agonist-naı¨ve. The ethics committee
approved the study and all patients gave written informed
consent. Table 1 illustrates the characteristics of the
enrolled patients.
Study protocol
The study was designed as a single centre open-label,
randomized, crossover conditions, with blind evaluation
study. It started in each patient two days after admission in
our Unit, when we had been able to confirm the substantial
improvement of the episode of AECOPD but we were still
feeling the need to monitor the patient’s blood gas status,
after a stay in emergency room fluctuating from three to 6
days.
All patients received indacaterol Breezhaler 150 mg (1
inhalation) þ placebo (1 inhalation) or indacaterol
Breezhaler 300 mg (2 inhalations) in two days, separated
from one another by 48 h in order to reduce the carry-over
effect of indacaterol.
Oral bronchodilators were not permitted during the
study. SABAs were permitted soon after each test when
required. Due to ethical considerations, all patients were
treated with oral prednisolone 30-mg daily and supple-
mental oxygen, when required, soon after the end of each
session. All patients also received a treatment with an
antibiotic (ciprofloxacin, clarithromycin or ceftriaxone).
Patients were asked not to consume cola drinks, coffee or
tea and not to smoke in the hours before and during the
investigation.
After a rest of 15 min and before the inhalation of
indacaterol, while the patient was breathing room air and
were seated in an armchair, samples of arterial blood (5 ml)
were removed for measurement of PaO2, PaCO2, and pH
Table 1 The baseline characteristics of the randomised patients.
Patients Gender Age
(yrs)
Height
(cm)
Weight
(kg)
BMI Smoke
(pack/y)
FEV1
% Pred
FVC
% Pred
PaO2/FiO2 Aea gradient
(normal)
1 M 62 162 68 25.0 50 38.6 68.4 257 1.98 (19.5)
2 M 78 170 80 27.7 Ex 50 23.4 44.1 243 21.23 (23.5)
3 F 73 137 36 19.6 50 67.4 85.6 329 15.73 (22.25)
4 F 79 162 58 22.1 40 23.6 39.5 295 1.48 (23.75)
5 F 79 152 40 17.3 Ex 60 39.9 61.5 290 36.23 (23.75)
6 F 81 168 64 23.9 Ex 40 64.7 95.9 343 20.23 (24.25)
7 M 71 167 65 23.3 70 23.4 50.0 348 14.37 (21.75)
8 M 73 170 65 22.5 80 22.3 60.9 305 26.98 (22.25)
9 M 78 160 65 23.8 110 36.6 54.7 343 20.23 (23.5)
10 F 75 162 67 25.5 Ex 50 26.6 67.8 243 34.48 (22.75)
11 M 72 173 55 18.2 Ex 70 38.8 72.4 348 27.98 (22)
12 M 54 158 78 25.7 28 46.4 78.3 267 42.48 (17.5)
Indacaterol and arterial blood gases 309with a blood gas analyser. The machine output was checked
daily with a standard test sample. Measurements were
performed before (at least 6 h after the last doses of short-
acting bronchodilators and corticosteroids) and 15, 30, 60,
120, 240 and 360 min after the administration of the drug,
always on room air. Spirometry was performed at the same
time intervals.
The change in PaO2 after each treatment, from the
baseline obtained on that day, was the primary outcome
variable. The magnitude of changes in blood-gas tensions
and spirometric values at each analysis time was compared
among treatments. The paired t-test and analysis of vari-
ance (ANOVA) were used to determine the significance of
differences among agents. Statistical significance was
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Both doses of indacaterol induced a significant mean in-
crease in FEV1 and FVC, but the improvement caused by
indacaterol 300 mg was larger (Fig. 1), although in some
patients both doses were unable to induce any significant
changes in FEV1 (Fig. 2).
The inhalation of both doses of indacaterol did not
induce significant changes in mean PaO2 values (Fig. 1).
However, the mean peak decrease in PaO2 over the 6 h was
5.9 mmHg (95% CI: 1.4 to 10.4) after indacaterol
150 mg and 6.2 mmHg (95% CI: 2.7 to 9.8) after inda-
caterol 300 mg, respectively. Individual changes in PaO2
showed that after inhaling indacaterol 150 mg, one patient
presented a decrease of 23 mmHg at 60 min, another a0 60 120 180 240 300 360
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Figure 2 Individual changes in FEV1 (solid line) and PaO2 (dashed line) over time after administration of indacaterol 150 mg
(squares) and 300 mg (triangles) via Breezhaler. Group A received first indacaterol 150 mg and then indacaterol 300 mg; Group B
received first indacaterol 300 mg and then indacaterol 150 mg.
310 P. Rogliani et al.decrease of 16 mmHg at 240 min and two other subjects a
decrease of 8 mmHg at 60 min and 30 min, respectively
(Fig. 2). After the inhalation of indacaterol 300 mg, one
patient showed a decrease in PaO2 of 18 mmHg at 240 min,
another of 13 mmHg at 30 min, a third of 11 Hg after 15 min
and a fourth of 10 Hg at 15 min (Fig. 2). The decreases in
PaO2 were mainly observed in the patients with the highest
basal PaO2. In any case, all values returned to normal
spontaneously. At 360 min, the mean value of PaO2 was
greater than baseline, with a statistically significant dif-
ference after indacaterol 300 mg (Fig. 1). Both indacaterol
150 and 300 mg induced a small and not significant mean
decrease in PaCO2 (Fig. 1). No patient showed a rise in
PaCO2.
Only indacaterol 150 mg significantly increased the
alveolar-arterial oxygen (Aea) gradient at 15 min (Fig. 3). Itshould be noted that in patients with an Aea gradient
higher than normal at baseline, both doses of indacaterol
did not induce any significant increase in this parameter as
opposed to what was observed in subjects with a normal
Aea gradient at baseline (Fig. 3). However, the observed
increases were always within the normal values.
We were unable to find a linear relationship between the
greatest changes in FEV1 and peak decreases in PaO2 with
both doses of indacaterol (Fig. 4).Discussion
The results of this pilot study, which is the first to best of
our knowledge that has explored the effect of indacaterol
on arterial blood gases and, consequently, must be
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Figure 3 Mean changes (se) in Aea gradient over time after administration of indacaterol 150 mg (squares) and 300 mg (tri-
angles) via Breezhaler (A, all patients; B, patients with a normal basal Aea gradient; C, patients with a high basal Aea gradient).
*P < 0.05 vs. baseline.
Indacaterol and arterial blood gases 311considered a preliminary note, suggest two important
points related to the use of this once-daily LABA.
First of all, despite being a long-acting bronchodilator
with high affinity for b2-adrenoceptors, indacaterol does
not seem to cause any significant change in blood gases
even in AECOPD, although some patients can present
transient episodes of oxygen desaturation that normalize
spontaneously in a very short time. In any case, we
observed a decrease in PaO2 mainly in patients with rela-
tively well-preserved PaO2. This is an important confirma-
tory finding. It has already been documented that b-
agonists cause an increase in VA/Q inequality in patients
having PaO2 values greater than 60 mmHg which results in a
moderate fall in the PaO2, whereas in patients with PaO2
values less than 60 mmHg, no significant changes in VA/Q
distributions or PaO2 after b-agonists has been observed
[20]. Reasons for this are undoubtedly complex but may
involve loss of hypoxic pulmonary vasoconstriction due to
morphologic changes of the pulmonary vasculature [20]. It
has been suggested that, in more severe COPD with more
prominent hypoxaemia, the pulmonary vascular tone is
more disturbed than in patients with less severe disease,
with the vessels more rigid and fixed, hence less liable to be
vasodilated by b-agonists [21].
The second main observation is that when the obstruc-
tion is very tight, it may be necessary to use a higher
indacaterol dose than that commonly prescribed for a COPD
patient who is in a stable clinical condition. This does not
seem to be a problem if we focus on the impact of inda-
caterol on blood gas levels because our data seem to rule
out that the increase in dose of a b2-agonist may aggravate
the PaO2 response, in contrast to what was originally
thought by Ferrer and co-workers [22]. In any case, we
already documented that the administration of indacaterol300 mg to patients admitted to emergency department for
an AECOPD resulted in a greater improvement of pulmonary
function compared with traditional therapy, with a statis-
tically significant improvement in PaO2 [23].
The transient decrease in PaO2 induced by inhaled b2-
agonists despite concomitant bronchodilation has been
attributed to the pulmonary vasodilator action of these
agents, increasing blood flow to poorly ventilated lung re-
gions resulting in greater VA/Q inequalities [21]. The
outcome of VA/Q mismatch is admixture of venous blood to
oxygenated blood leading to a decrease in PaO2, the arte-
rial saturation of haemoglobin with oxygen, and thereby
the arterial oxygen content that reaches the left-sided
circulation [24]. However, although LABAs have an acute
vasodilator action in the airways, the modest contribution
of bronchial circulation to the lung’s blood flow indicates
that it does not participate significantly in gas exchange
and suggests that the impact of the vasodilating effect of
b2-agonists on V/Q inequality is small and unimportant [25].
Multiple effects in different compartments involved in gas
exchange (including airflow and blood flow distribution) can
cause a decrease in PaO2 [24]. Alterations that affect the
post-alveolar (capillary) side, for example, a change of the
central venous oxygen saturation of haemoglobin due to an
alteration in cardiac output, changes in ventilation or acute
bronchial obstruction can affect PaO2 and therefore need to
be taken into consideration [25]. Unfortunately, these con-
structs were not verified in the present study, whichwas only
focused on the impact of indacaterol on arterial blood gases
and the possible link between bronchodilation and decrease
in PaO2. What, however, this study allows to exclude is that
there is a dose-dependent effect of indacaterol on arterial
blood gases. Furthermore, bronchodilation is completely
independent of this systemic effect.
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312 P. Rogliani et al.Karpel co-workers [4] reported that metaproterenol
produced a mean decline in PaO2 of 6.2 mmHg during
AECOPD. Nonetheless, the small effect of indacaterol on
blood gases of our patients with AECOPD fits rather well
with the observation of Polverino and co-workers [21], who
showed that the administration of 5.0 mg salbutamol at the
time of exacerbation did not aggravate the already
compromised pulmonary gas exchange. A weaker (or even
absent) hypoxic pulmonary vascular response related more
to acutely severe alveolar hypoxia than to a permanent
structural derangement of the pulmonary vasculature was
suggested a the most likely explanation of the lack of gas
exchange response to salbutamol in AECOPD [21]. However,
also other explanations were postulate [26]. For example,
b2-agonists can minimize the subsequent release of other
inflammatory mediators into the pulmonary circulation,
with vasodilator effects during AECOPD that can disturb the
underlying V/Q imbalance [26]. Moreover, the potential of
b2-agonist-induced inhibitory effects on the postcapillary
bronchial venoconstriction and airway microvascular
leakage, possibly amplified by their potent relaxant effect
on conducting airways, cannot be overlooked [26].
Whatever the mechanisms behind the changes in arterial
blood gases, our findings were broadly reassuring. They
indicated that indacaterol up to 300 mg is a potentbronchodilator that may induce small, transient decrease in
PaO2 mainly in patients with relatively well-preserved PaO2
and, consequently, there appeared to be no clinical con-
sequences of these PaO2 abnormalities. Moreover, our study
suggests that an increase in PaCO2 following a high dose of
indacaterol is uncommon in patients with AECOPD.
However, since all our patients were taking inhaled b2-
agonists regularly prior to be studied, and it is well-known
that regular use of these agents can lead to down-
regulation of their systemic response [13], it is now
mandatory to repeat the study in b2-agonist-naı¨ve subjects.
Moreover, since Polverino and co-workers [21] documented
that while in convalescence, the gas exchange response to
an inhaled b2-agonist is deleterious resulting in small dec-
rements in PaO2 due to V/Q worsening, the study must be
repeated in patients suffering from stable COPD.Conflict of interest statement
We declare that we have no conflict of interest with this
study that has not been sponsored by any Drug Company.
However, Mario Cazzola is a member of a scientific advisory
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